Literature DB >> 34889369

Evidence-Based Minireview: Should warfarin or a direct oral anticoagulant be used in patients presenting with thrombosis in the splanchnic or cerebral veins?

Carol Mathew1, Marc Zumberg1.   

Abstract

Case 1: A 23-year-old female third-year medical student who has no medical history seeks treatment for abdominal distention. She takes an estrogen-containing birth control pill and does not smoke or consume alcohol. Family history is unremarkable. Physical examination is significant for abdominal distention, and an abdominal fluid wave is detected. Complete blood count is normal. Imaging confirms occlusive thrombosis of the main portal vein. On endoscopy, grade 1 to 2 esophageal varices are noted and banded. Unfractionated heparin is begun. Subsequent workup reveals a homozygous factor V Leiden mutation. Long-term anticoagulation is planned, and she asks if warfarin can be avoided given her hectic ward rotations, erratic diet, and need for monitoring. Case 2: A 35-year-old woman who has no medical history seeks treatment for progressively worsening posterior headaches for 1 week. Magnetic resonance imaging of the brain shows dural sinus thrombosis with associated small areas of petechial cerebral hemorrhage. She is started on a continuous unfractionated heparin infusion and admitted to the hospital for further observation. Her grandmother is on warfarin for atrial fibrillation, and the patient would prefer to avoid warfarin because she does not think she can comply with the frequent monitoring that will be required. She inquires about other oral anticoagulant options for her condition.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34889369      PMCID: PMC8791162          DOI: 10.1182/hematology.2021000319

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  37 in total

1.  EASL Clinical Practice Guidelines: Vascular diseases of the liver.

Authors: 
Journal:  J Hepatol       Date:  2015-10-26       Impact factor: 25.083

2.  Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients.

Authors:  Rajesh Shankar Iyer; Ramakrishnan Tcr; Saleem Akhtar; Karunakaran Muthukalathi; Praveen Kumar; Kumar Muthukumar
Journal:  Clin Neurol Neurosurg       Date:  2018-10-31       Impact factor: 1.876

3.  Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis.

Authors:  Amr Shaaban Hanafy; Sherief Abd-Elsalam; Mohammed M Dawoud
Journal:  Vascul Pharmacol       Date:  2018-06-07       Impact factor: 5.773

4.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

5.  Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis.

Authors:  S F de Bruijn; J Stam
Journal:  Stroke       Date:  1999-03       Impact factor: 7.914

6.  Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey.

Authors:  Nicoletta Riva; Marc Carrier; Alex Gatt; Walter Ageno
Journal:  Res Pract Thromb Haemost       Date:  2020-09-11

7.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).

Authors:  José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

8.  New Oral Anticoagulants versus Warfarin for Cerebral Venous Thrombosis: A Multi-Center, Observational Study.

Authors:  Mohammad Wasay; Maria Khan; Haris Majid Rajput; Salman Farooq; Mohammed Ibrahim Memon; Suhail Abdulla AlRukn; Abdul Malik; Foad Abd-Allah; Raja Farhat Shoaib; Rizwana Shahid; Sadia Nishat; Safia Awan
Journal:  J Stroke       Date:  2019-05-31       Impact factor: 6.967

9.  Direct oral anticoagulants for unusual-site venous thromboembolism.

Authors:  Nicoletta Riva; Walter Ageno
Journal:  Res Pract Thromb Haemost       Date:  2021-01-28

10.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

Authors:  Giancarlo Agnelli; Cecilia Becattini; Guy Meyer; Andres Muñoz; Menno V Huisman; Jean M Connors; Alexander Cohen; Rupert Bauersachs; Benjamin Brenner; Adam Torbicki; Maria R Sueiro; Catherine Lambert; Gualberto Gussoni; Mauro Campanini; Andrea Fontanella; Giorgio Vescovo; Melina Verso
Journal:  N Engl J Med       Date:  2020-03-29       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.